|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Alvocidib
Alvocidib is a synthetic N-methylpiperidinyl chlorophenyl flavone
compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces
cell cycle arrest by preventing phosphorylation of cyclin-dependent
kinases (CDKs) and by down-regulating cyclin D1 and D3 expression,
resulting in G1 cell cycle arrest and apoptosis. This agent is also a
competitive inhibitor of adenosine triphosphate activity. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus)
Current developer: Sanofi-Aventis
Inc.
|
MedKoo Code#:
200180
|
|
Name:
Alvocidib
|
|
CAS#:
131740-09-5
(HCl salt) or 146426-40-6 (free base)
Synonym: Flavopiridol；HMR 1275
IUPAC/Chemical name:
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
hydrochloride
|
|
Chemical structure
|
Theoretical analysis
|
|
|
MedKoo Code#: 200180
Name: Alvocidib
CAS#: 146426-40-6 (free base)
Chemical Formula: C21H20ClNO5
Exact Mass: 401.10300
Elemental Analysis: C, 62.77; H, 5.02; Cl,
8.82; N, 3.49; O, 19.91
|
|
Availability and price:
Alvocidib (Flavopiridol, free
base form) is in stock
10 mg / $150.00
20 mg / $210.00
50 mg / $450.00
100mg / $650.00
200mg / $950.00
Multiple grams available at
low prices.
(LC20130404)
To inquire the quotation and lead time of custom synthesis for this agent, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
1: Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB,
Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader
E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. A
Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed,
Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with
Excess Blasts-2. Clin Cancer Res. 2013 Mar 20. [Epub ahead of print]
PubMed PMID: 23515411.
2: Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL,
Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, Maguire JL,
Shridhar V, Kukla AK, Voll KJ, Mauer MJ, Colevas AD, Wright J, Doyle LA,
Erlichman C; Mayo Phase 2 Consortium (P2C); North Central Cancer
Treatment Group (NCCTG). A phase 2 trial of flavopiridol (Alvocidib) and
cisplatin in platin-resistant ovarian and primary peritoneal carcinoma:
MC0261. Gynecol Oncol. 2012 Oct;127(1):55-62. Epub 2012 Jun 1. PubMed
PMID: 22664059.
3: Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja
N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart
RK, Peer C, Figg WD Sr, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts
JD, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and
alvocidib (flavopiridol; NSC 649890) in patients with recurrent or
refractory B-cell neoplasms. Clin Cancer Res. 2011 May
15;17(10):3388-97. doi: 10.1158/1078-0432.CCR-10-2876. Epub 2011 Mar 29.
PubMed PMID: 21447728; PubMed Central PMCID: PMC3096752.
4: Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L,
Kortmansky J, Kelsen DP, Schwartz GK, O'Reilly EM. A phase II study of
flavopiridol (Alvocidib) in combination with docetaxel in refractory,
metastatic pancreatic cancer. Pancreatology. 2009;9(4):404-9. doi:
10.1159/000187135. Epub 2009 May 19. PubMed PMID: 19451750.
5: Sato S, Kajiyama Y, Sugano M, Iwanuma Y, Sonoue H, Matsumoto T,
Tsurumaru M. Alvocidib (Flavopiridol) suppresses tumor growth in SCID
mice with human esophageal cancer xenografts without inducing apoptosis.
Surg Oncol. 2006 Aug;15(2):107-13. Epub 2006 Nov 13. PubMed PMID:
17097874.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
